Navigation Links
Fewer adverse cardiac events at one year

WASHINGTON, DC OCTOBER 22, 2007 Late breaking results from the SPIRIT III trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that after 12 months, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the original vessel blockage after using a Xience V everolimus-eluting coronary stent than a Taxus paclitaxel-eluting stent.

The rate of the primary endpoint, in-segment late loss (a measure of how much the artery re-narrows following stenting) was also reduced by 50% with the Xience V stent compared to Taxus. There were no significant differences in other secondary endpoints between the two stent types, including target vessel failure (a combination of repeat procedures anywhere in the involved blood vessel and adverse cardiac events), as well as stent thrombosis (dangerous blood clots that can form within the stent).

Both the primary endpoint of the trial and the major secondary endpoint were met, said Gregg W. Stone, MD, Chairman, Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center. Moreover, the reduction in major adverse cardiac events with the Xience V stent compared to the Taxus stent is an important finding that signifies improved long-term outcomes for patients with heart disease. Given this positive finding, which has never before been seen in a pivotal drug-eluting stent vs. stent trial, coupled with the ease of use of Xience, will result in this device becoming a favored drug-eluting stent for clinicians treating coronary disease.

Further studies are required to determine whether there are meaningful differences between the two stent types in low frequency safety events, and in important subgroups, Stone added.

SPIRIT III 12-Month Results

Everolimus-Eluting Stent Paclitaxel-Eluting Stent
Target Vessel Failure 8.3 percent 10.8 percent
MACE 5.8 percent 9.9 percent
Cardiac Death .8 percent .9 percent
MI 2.6 percent 3.7 percent
Ischemia-Driven TLR 3.3 percent 5.6 percent

The SPIRIT III trial was designed as a prospective, randomized, active-controlled, single blind, multi-center clinical trial, which enrolled 1,002 patients (65 different U.S. sites) with coronary artery disease.


Contact: Irma Damhuis
Cardiovascular Research Foundation

Related medicine news :

1. Chemotherapy Pill Has Fewer Side Effects Than IV
2. Fewer teeth & Increased Ischemic Stroke risk
3. Heart Patients More At Risk Get Fewer Medicines
4. Fewer People Die Due To Cancer
5. Fewer Breast Cancer Patients to Get Chemo
6. Fewer Blacks Undergo Lung Cancer Surgery
7. Thailand had Fewer AIDS-Related Deaths, New HIV Cases In 2005
8. Fewer Neurons in Amygdala of Autistic Males
9. Women With Fewer Periods Have Low Risk Of Gynecological Cancer
10. Fewer Doctors Treating For Free
11. Fruits & Vegetables Makes You Look Younger With Fewer Wrinkles
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... recognized once again for its stellar workplace culture with the company’s Cincinnati office ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer ... Court of Connecticut on behalf of a home health care worker who provided companionship ... former home health care workers employed by Humana, Inc., Humana at Home, Inc., and ...
(Date:11/25/2015)... ... ... Dental professionals who would like to become more proficient on their knowledge of ... Advanced Implant Mentoring (AIM) CE course. Courses will be held on December 3rd, 4th ... Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to announce that individuals ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 23rd ... Tri Lite’s personal heating products business. Cozy Products explains what this means ... that fit in well with the Cozy Products business model: to sell personal heaters ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... decades of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled ... 5-6. , For 65 years, Brillianteen has been a treasured tradition ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... N.Y. , Nov. 25, 2015  Henry Schein, ... and services to office-based dental, medical and animal health ... (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion , ... broadest array of open solutions designed to help any ... Click here for a schedule of experts ...
(Date:11/25/2015)... issue of United States patent No. 9,192,509  entitled: " Methods and Apparatus ... AVACEN 100 dry heat therapy medical device and specific methods of use, referred to by the ... - ... ... ...
(Date:11/25/2015)... YORK , November 25, 2015 ... market of self-monitoring blood glucose devices was valued at ... grow with a CAGR of 5.7% during 2015 - ... geriatric population and increasing prevalence of diabetes. In addition, ... diabetes care is also contributing to the growth of ...
Breaking Medicine Technology: